Observation on the Therapeutic Effect of Metal-Clearing Phlegm-Transforming Decoction with Syndrome Differentiation and Modification Combined with Ambroxol Hydrochloride in the Treatment of Chronic Bronchitis of Phlegm Heat Stagnation Lung Type
Objective Exploring the clinical effect of Metal-Clearing Phlegm-Transforming Decoction combined with ambroxol hydrochloride in the treatment of chronic bronchitis(CB)of phlegm heat stagnation lung type based on syndrome differentiation and modification.Methods 84 CB patients admitted to our hospital from July 2020 to July 2023 were selected as the research subjects,divided them into a control group and an observation group using a random number table method,with 42 cases in each group.The control group was treated with ambroxol hydrochloride,while the observation group was treated with modified Metal-Clearing Phlegm-Transforming decoction based on syndrome differentiation in addition to the control group,both groups were treated continuously for 10 days.The disappearance time of disease symptoms,forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)and rate in the first second(FEV1/FVC),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),interleukin-8(IL-8)TCM syndrome score and incidence of adverse reactions were compared between the two groups.Results After treatment,the disappearance time of wheezing,coughing,sputum production,and lung rales in the observation group was(5.19±1.02)d,(3.52±0.43)d,(4.03±0.48)d,and(5.41±1.15)d,respectively,which were shorter than the control group's(7.08±1.15)d,(4.69±0.48)d,(4.82±0.54)d,and(7.25±1.24)d,respectively,the differences between groups were statistically significant(P＜0.05).After treatment,the FVC,FEV1 of the observation group were(3.75±0.49)L,(2.45±0.33)L,respectively,greater than the control group's(3.06±0.42)L,(1.86±0.25)L,and the FEV1/FVC was(65.33±6.05)%,higher than the control group's(60.78±5.29)%,the differences between groups were statistically significant(P＜0.05).After treatment,the levels of IL-6,IL-8 and TNF-α in observation group were(36.31±3.15)ng/L,(223.41±22.13)ng/mL,and(11.12±1.35)pg/mL,respectively,lower than the control group's(41.14±4.23)ng/L,(254.15±26.65)ng/mL,and(15.09±1.41)pg/mL,respectively,the differences between groups were statistically significant(P＜0.05).After treatment,the observation group had phlegm yellow viscosity,cough shortness of breath,and dry mouth scores of(0.85±0.13)points,(0.72±0.11)points,and(0.69±0.12)points,respectively,which were lower than the control group's(1.04±0.15)points,(0.95±0.14)points,and(0.85±0.14)points,the differences between groups were statistically significant(P＜0.05).Comparison of adverse reactions between two groups,there was no statistically significant difference between groups(P＞0.05).Conclusion The combination of modified Metal-Clearing Phlegm-Transforming Decoction and ambroxol hydrochloride can improve the therapeutic effect of phlegm heat stagnation lung type CB based on syndrome differentiation,,accelerate the regression of inflammation,reduce lung function damage,relieve disease symptoms,and is safe and reliable.
Chronic bronchitisSyndrome differentiation and modification of Metal-Clearing Phlegm-Transforming DecoctionAmbroxol hydrochlorideInflammation level
NETL
NSTL
万方数据
